within Pharmacolibrary.Drugs.C_CardiovascularSystem.C09B_AceInhibitorsCombinations.C09BB05_RamiprilAndFelodipine;

model RamiprilAndFelodipine
  extends Pharmacolibrary.Drugs.ATC.C.C09BB05;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>C09BB05</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Combination of ramipril, an angiotensin-converting enzyme (ACE) inhibitor, and felodipine, a dihydropyridine calcium-channel blocker, used as an antihypertensive therapy for the treatment of essential hypertension. This combination is approved and used in clinical practice for blood pressure control, particularly in patients requiring therapy from both classes.</p><h4>Pharmacokinetics</h4><p>No dedicated published pharmacokinetic model or original population PK parameters are available for the fixed combination product of ramipril and felodipine (C09BB05). Below are estimated representative parameters based on the PK of ramipril and felodipine separately in healthy adults following oral administration with typical clinical doses.</p><h4>References</h4><ol><li><p>Ahmed, S, et al., &amp; Bakr Ali, MF (2017). Ultrasound assisted dispersive liquid-liquid microextraction coupled with high performance liquid chromatography designated for bioavailability studies of felodipine combinations in rat plasma. <i>Journal of chromatography. B, Analytical technologies in the biomedical and life sciences</i> 1046 200â€“210. DOI:<a href=\"https://doi.org/10.1016/j.jchromb.2017.01.034\">10.1016/j.jchromb.2017.01.034</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/28189955/\">https://pubmed.ncbi.nlm.nih.gov/28189955</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end RamiprilAndFelodipine;
